NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed treatments for serious diseases.  The Company’s proprietary technology enables rapid delivery of drugs into the bloodstream, which may result in faster onset of action and potential patient benefits in compliance, convenience and safety.  NovaDel’s most advanced candidates target nausea, insomnia, migraine headaches and disorders of the central nervous system (CNS).

By focusing its proprietary delivery technology on proven pharmaceuticals, NovaDel leverages existing safety and efficacy data to accelerate the development and registration process. NovaDel has entered commercial partnerships for its lead candidates and may develop internal commercialization capabilities to support certain products in the future.

NovaDel is headquartered in Flemington, NJ.  Its common shares trade on the American Stock Exchange under the symbol:  NVD.